Related Experiment Video
Updated: Jul 6, 2026
06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
The comparative effectiveness and cost-effectiveness of vitreoretinal interventions
Melissa M Brown1, Gary C Brown, Heidi C Brown
1Center for Value-Based Medicine, Flourtown, USA. mbrown@valuebasedmedicine.com
Current Opinion in Ophthalmology
|April 15, 2008
Summary
Vitreoretinal interventions demonstrate strong comparative effectiveness and cost-effectiveness against other healthcare treatments. These interventions offer significant value, measured by quality-adjusted life-year gains, making them a worthwhile investment in patient outcomes.
Area of Science:
- Ophthalmology
- Health Economics
- Comparative Effectiveness Research
Background:
- The literature increasingly emphasizes comparative effectiveness of medical interventions, often within similar classes.
- Value-based medicine provides a framework to compare interventions across disparate fields of healthcare.
- This report focuses on recent comparative effectiveness studies within the vitreoretinal literature.
Purpose of the Study:
- To review recent comparative effectiveness studies in vitreoretinal medicine.
- To evaluate the value and cost-effectiveness of vitreoretinal interventions.
- To discuss the application of value-based medicine principles to ophthalmology.
Main Methods:
- Analysis of recent comparative effectiveness studies in vitreoretinal interventions.
- Evaluation of quality-adjusted life-year (QALY) gains as a measure of value.
- Assessment of cost-utility ratios ($/QALY) for cost-effectiveness analysis.
Main Results:
- Vitreoretinal interventions exhibit good to excellent comparative effectiveness when contrasted with common healthcare treatments (e.g., osteoporosis, hyperlipidemia).
- These interventions are generally cost-effective, particularly when considering a threshold of $100,000 per quality-adjusted life-year.
- The majority of evaluated vitreoretinal interventions provide substantial value and demonstrate cost-effectiveness.
Conclusions:
- Value in healthcare can be quantified using quality-adjusted life-year gain or percentage improvement in value, enabling direct comparison across all interventions.
- Cost-utility analysis, expressed as dollars per quality-adjusted life-year, allows for cost-effectiveness comparisons across diverse medical interventions.
- Vitreoretinal interventions represent a valuable and cost-effective component of modern healthcare.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...